Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06832865 · ClinicalTrials.gov registry record · Phase 2
ELISA in Relapsed/Refractory MM
A Phase 2 study of Relapsed/Refractory Multiple Myeloma and Relapsed Refractory Multiple Myeloma (RRMM), sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT06832865: Recruiting Phase 2 study of Relapsed/Refractory Multiple Myeloma and Relapsed Refractory Multiple Myeloma (RRMM), sponsored by Massachusetts General Hospital.
NCT06832865 is a Phase 2 study of Relapsed/Refractory Multiple Myeloma and Relapsed Refractory Multiple Myeloma (RRMM) that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 170-participant average among 14 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (82% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06832865, a Phase 2 study of Relapsed/Refractory Multiple Myeloma and Relapsed Refractory Multiple Myeloma (RRMM), is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is an open-label phase 2 study of elranatamab in combination with isatuximab administered subcutaneously in patients with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior lines of therapy and who have had previous treatment with both immunomodulatory drugs (IMiDs) and a proteasome inhibitor (PI). The subcutaneous injection method of isatuximab administration, including the device used to administer isatuximab, is investigational.
Primary Outcome
Objective Response will be classified using the International Myeloma Working Group (IMWG) Uniform Response criteria. The rate (ORR) will be calculated using a Simon's two-stage design to test the null hypothesis that the ORR ≤ 0.40 versus the alternative that ORR ≥ 0.60. All patients who receive at least one complete cycle of treatment will be included in a response evaluation. Participants who do not complete cycle 1 (i.e., due to disease progression or who die prior to the end of cycle 1) wil
Conditions Studied
Interventions
- DRUG elranatamab
- DRUG Isatuximab SC
- DEVICE Isatuximab SC-OBDS
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-08-14 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 2 |
What NCT06832865 shows while recruiting
NCT06832865 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 170-participant average among 14 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Relapsed/Refractory Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which elranatamab is the first listed.
NCT06832865 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06832865 about?
NCT06832865 is a clinical study titled "ELISA in Relapsed/Refractory MM". This is an open-label phase 2 study of elranatamab in combination with isatuximab administered subcutaneously in patients with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior lines of therapy and who have had previous treatment with both immunomodulatory drugs (I...
What is the current status of trial NCT06832865?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-08-14. Estimated completion is 2028-12-01.
What conditions does trial NCT06832865 study?
This clinical trial studies the following conditions: Relapsed/Refractory Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM).
What interventions are being tested in trial NCT06832865?
The interventions under investigation include: elranatamab (DRUG), Isatuximab SC (DRUG), Isatuximab SC-OBDS (DEVICE).
Who is sponsoring clinical trial NCT06832865?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06832865 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06832865's enrollment target sits among peer trials
30 14th of 14 the lowest of 14 other Relapsed/Refractory Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsed/Refractory Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Cevostamab Following CAR T Cell Therapy for RRMM
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RECRUITING · Phase 1
-
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI